is a cyclin-dependent kinase subunit (cKS) family member that participates in cell cycle regulation. Few studies have investigated its involvement in gastric cancer. In this study, we focused on the clinical and biological significance of CKS2 overexpression in gastric cancer. The expression of CKS2 mRNA was studied by real-time quantitative reverse transcription polymerase chain reaction, and the expression status in each tumor was examined to varify whether any correlation existed with clinical and pathological factors. In addition, an immunohistochemical study was performed in selected samples. Moreover, we examined the impact of CKS2-siRNA in a gastric cancer cell line. A significantly higher expression of CKS2 mRNA was found in tumor tissues compared to paired normal tissues (p<0.01). Immunohistochemical analyses led to similar results. The overall five-year survival rate was significantly higher in the low CKS2 expression group (59.9%) than in the high CKS2 expression group (23.9%) (p<0.01). Univariate and multivariate analysis showed that CKS2 expression status was an independent prognostic factor (relative risk, 1.41; 95% confidence interval, 1.01-1.97; p<0.05). Moreover, the inhibition of cellular proliferation by CKS2-siRNA was observed in a gastric cancer cell line. CKS2 is one of the gastric cancerrelated genes that correlates with biological aggressiveness and poor prognosis of gastric cancer. Thus, CKS2 is a possible candidate gene for diagnosis, as well as targeted molecular diagnosis and therapy in gastric cancer.
Introduction
cell cycle phase transitions are regulated by cyclin-dependent protein kinases (cdks) and their cyclin binding partners. cell cycle regulatory failure is associated with the development or the progression of cancer (1) (2) (3) (4) (5) . cyclin-dependent kinase subunit (cKS) proteins play a role in mitosis, and they bind to and regulate the activity of the cdks (6, 7) . In mammals, there are two homologs, CKS1 and CKS2 (8) . Both CKS1 and CKS2 consist of 79 amino acids, and show 81% homology. CKS1 is a specific co-factor that is necessary for the degradation and ubiquitination of p27 by ScF Skp2 . Human cKS1 binds to Skp2 and increases the binding of threonine 187-phosphorylated p27 to Skp2 (9, 10) . However, CKS2 has been termed CDC28 protein kinase regulatory subunit 2, as it binds to the catalytic subunit of cdk. CKS2 activates the cDc2-cyclin B complex that binds to a part of cdk and controls cell cycle transitions (11) .
gastric cancer is one of the most aggressive forms of cancer of the gastrointestinal tract and it is lethal when it is not diagnosed at an early stage. A high incidence of gastric cancer has persisted in Japan, South America and Eastern European countries. According to surveillance, epidemiology, and end results (SEER) data, an estimated 21,500 new cases of gastric cancer were diagnosed in the United States in 2008, and an estimated 10,880 patients will died of gastric cancer in spite of improvements in surgery and chemotherapy (12) . In Japan, it is the second most frequent form of cancer and approximately 50,000 people die of the disease annually (13) (14) (15) . To improve the survival rates from gastric cancer, the development of new treatments is crucial.
Molecular events resulting in the progression of gastric cancer are complex and poorly understood. However, some (16, 17) . Furthermore, the discovery of novel molecular markers has facilitated the understanding of the molecular and cellular mechanisms underlying the development and progression of gastric cancer (18) . It would be beneficial to identify novel gastric cancer molecular markers that could help both early diagnosis and treatment of the disease. We have previously shown that CKS1 is a predictive marker for the prognosis of gastric cancer patients (19) . However, there are few studies on the clinical significance of CKS2 in human gastric cancer. In this study, we investigated CKS2 expression in 109 gastric cancer patients and analyzed its clinical significance. (20) . The tumor and paired normal tissue samples were immediately frozen in liquid nitrogen and kept at -80˚C until the extraction of RNA.
Material and methods

Cell
RNA extraction and complementary DNA (cDNA) synthesis.
Total RNA was extracted from cell lines and samples using guanidinium thiocyanate as described previously (21) . The quality of the RNA samples was confirmed. cDNA was synthesized from 8 µg of total RNA using random hexamer primers and M-MLv reverse transcriptase (Invitrogen corp.) as described previously (4) .
Oligonucleotide primers for CKS2 cDNA amplification by reverse transcription polymerase chain reaction (RT-PCR).
The oligonucleotide primers for CKS2 were as follows: Sense, 5'-TgTcTgAAgAggAgTggAggA-3' and antisense, 5'-cAT gcAcAggTATggATgAAA-3'. To avoid amplification of contaminating genomic DNA, these primers spanned more than two exons. Monitoring was performed according to the manufacturer's instructions, as described previously (22) . A master mix was prepared on ice, containing 1 µl of cDNA, 2 µl of DNA Master SyBR-green I mix, 50 ng of primers and 2.4 µl of 25 mM Mgcl 2 . The final volume was adjusted to 20 µl with sterile water. After the mixture was loaded into the glass capillary tube, real-time quantitative RT-PcR was performed. The amplification conditions were as follows: Initial denaturation at 95˚C for 10 min, followed by 35 cycles of denaturation at 95˚C for 10 sec, annealing at 62˚C (60˚C for GAPDH) for 10 sec, and elongation at 72˚C for 10 sec. To distinguish specific from non-specific products and primer dimers, melting curve analysis was carried out. To evaluate specific mRNA expression in the samples, a standard curve was produced for each run measuring four points of the human control cDNA (clontech Laboratories). The concentration of each sample was calculated by observing its crossing point relative to the standard curve.
Immunohistochemistry. Immunohistochemical studies of CKS2 were performed on formalin-fixed, paraffin-embedded surgical specimens obtained from gastric cancer patients. The tissue sections were paraffinized and soaked in 0.01 M sodium citrate buffer (pH 7.4) for 20 min to retrieve the cell antigen. After blocking, the antigen-antibody reaction was incubated overnight at 4˚C. Tissue sections were immunohistochemically stained using the streptavidin-biotin peroxidase method (LSAB + system-HRP; Dako, Kyoto, Japan). All sections were counterstained with haematoxylin. The primary mouse monoclonal antibodies against cKS2 (Lifespan Biosciences Inc., WA, USA) were used at a dilution of 1:50.
Of the 109 total cases, we examined the cKS2 protein expression status in 26 available patient samples. In those 26 cases, 13 showed a high expression level of CKS2 mRNA, whereas the remaining 13 cases showed a low expression level of CKS2 mRNA. The border of the two groups was defined by the median of CKS2 mRNA expression status in the tumor. All sections were independently examined by an investigator (H.I.).
CKS2 RNA interference. CKS2-specific siRNA (Silencer™ Predesigned siRNA sense, 5'-ggAgAcUUggUgUccAA cATT-3', and antisense, 5'-UgUUggAcAccAAgUcUc cTc-3') and negative control siRNA (Silencer Negative control no. 1 siRNA) were purchased from Ambion, USA. The siRNA oligomer was diluted with Opti-MEM I medium (Invitrogen corp.). The diluted siRNA oligomer was mixed with the diluted Lipofectamine™ RNAiMAX (Invitrogen corp.) and incubated for 20 min at room temperature to allow siRNA-RNAiMAx complexes to form. The siRNA was added to each well to a final concentration of 125 pmol/ml. Then, MKN74 cells were seeded at 3x10 5 cells per well in a final volume of 2 ml in six-well, flat-bottom microtiter plates. The cells were incubated in 5% cO 2 at 37˚C.
In vitro proliferation assay. The cell proliferation rate was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Roche Diagnostics corp., IN, USA). The cells were plated at a density of 1x10 4 cells per well in 96-well, flat bottom microtiter plates and were harvested and counted on days zero to four. After incubation, 10 µl of MTT labeling reagent were added to each well. The microtiter plate was incubated for 4 h in 5% cO 2 at 37˚C. Solubilization solution (100 µl) was added to each well. The plate was allowed to stand overnight in an incubator in 5% cO 2 at 37˚C. After checking for complete solubilization of purple formazan crystals, the spectrophotometric absorbance of the samples was measured using a model 550 microplate reader (Bio-Rad Laboratories, cA, USA), at a wavelength of 570 nm corrected to 655 nm. Each independent experiment was performed three times.
In vitro invasion assay. In vitro invasion assays were carried out using the CultreCoat™ 24 Well BME-Coated Cell Invasion Assay (Trevigen, MD, USA). cells were placed in the upper chamber, and the lower chamber was filled with 750 µl of RPMI-1640 medium supplemented 10% FBS. After 48 h of incubation in 5% cO 2 at 37˚C, the membranes were labeled with a calcein AM solution. The invasive cells that had migrated through the membrane to the lower surface were read in a fluorescence plate reader at a wavelength of 485 nm corrected to 530 nm. Each independent experiment was performed three times.
In vitro migration assay. In vitro migration assays were carried out using the Cultrex™ 24 Well Cell Migration Assay (Trevigen). cells were placed in the upper chamber, and the lower chamber was filled with 750 µl of RPMI-1640 medium supplemented with 10% FBS. After 48 h of incubation in 5% cO 2 at 37˚C, the membranes were labeled with a calcein AM solution. The cells that had migrated through the membrane to the lower surface were read in a fluorescence plate reader at a wavelength of 485 nm corrected to 530 nm. Each independent experiment was performed three times.
Apoptosis assay. The cells were cultured at 3x10 5 cells per well in a final volume of 2 ml in six-well, flat-bottom microtiter plates. The cells were incubated in 5% cO 2 at 37˚C. The cells were then washed and suspended in 0.5 ml of binding buffer, and annexin V/fluorescein isothiocyanate/propidium iodide labeling was performed following the manufacturer's instructions (BD Biosciences). Analysis was performed with a FAcScan instrument. A total of 5,000 cells were collected for each sample, and the data were analyzed with cellQuest software (Becton-Dickinson, San Jose, cA, USA). Each independent experiment was performed three times.
Flow cytometric analysis. The cells were harvested and rinsed twice with PBS. The cells were then fixed and permeated with the BD Active caspase 3 Kit (Becton-Dickinson). Dissociated cells were stained with FITc-conjugated anti-caspase 3 antibody and incubated for 30 min at room temperature. A total of 10,000 cells were collected for each sample using FAcScan (Becton-Dickinson), and the data were analyzed with cellQuest software. Each independent experiment was performed three times.
Western blot analysis. Total protein was extracted from the sample with PRO-PREP (iNtRON Biotechnology, gyeonggi-do, Korea) on ice 30 min. Aliquots of total protein were applied to 18% polyacrylamide gels (Bio-Rad Laboratories). After electrophoresis, the samples were electroblotted onto a pure nitrocellulose membrane (Bio-Rad) at 0.2 A for 2 h at 4˚C. Bax protein was detected using rabbit polyclonal antibody (Santa cruz Biotechnology, cA, USA) at a dilution of 1:200. The blots were developed with horseradish peroxidase linked anti-rabbit immunoglobulin (gE Healthcare, cT, USA) at a dilution of 1:1,000. The protein level of Bax was normalized to the level of β-actin protein (cytoskeleton, Inc., cO, USA) at a dilution of 1:1,000. The blots were developed with horseradish peroxidase-linked anti-mouse immunoglobulin (gE Healthcare) at a dilution of 1:1,000. Signals were detected using Western blotting detection EcL reagents (gE Healthcare).
Statistics. For continuous variables, the data were expressed as the means ± standard deviation (SD). The relationship between CKS2 mRNA expression and clinicopathological factors was analyzed using the χ 2 test and the Student's t-test. Overall survival curves were plotted according to the KaplanMeier method and the generalized log-rank test was applied to analyze the survival curves. Prognostic factors were evaluated by univariate and multivariate analyses (cox proportional hazard regression model). The cell proliferation assay was assessed with the Repeated ANOvA method. All differences were deemed significant at the level of p<0.05. Statistical analysis was performed using JMP software (SAS Institute Inc, cary, Nc, USA).
Results
CKS2 mRNA expression in gastric cancer cell lines and clinical samples.
The expression of CKS2 mRNA in human gastric cancer cell lines and clinical samples was determined by RT-PcR (Fig. 1) . The expression of CKS2 mRNA was observed in all the human gastric cancer cell lines that were surveyed (KATOIII, MKN1, MKN7, MKN28, MKN45, MKN74, NUgc3 and NUgc4) (Fig. 1A) . We also performed RT-PcR analyses of CKS2 in gastric cancer samples and paired normal samples obtained from seven patients. A significantly higher expression of CKS2 mRNA was observed in the tumor tissues than in the paired normal tissues (Fig. 1B) . We confirmed the expression of the CKS2 mRNA in clinical samples by real-time quantitative RT-PcR (Fig. 1c) . Realtime quantitative RT-PcR analysis on 109 paired clinical samples showed that 62 of 109 cases (56.9%) exhibited higher levels of CKS2 mRNA in the tumors than in the paired normal samples. The mean expression value of CKS2 mRNA in the tumor samples, 0.82±0.68 (mean ± SD, normalized to GAPDH gene expression), was significantly higher than the value, 0.59±0.44, in the corresponding normal samples (p<0.01; Student's t test). For further analysis of tumors, the cases were divided into high (n=40) and low (n=69) expression groups according to the average CKS2 mRNA expression status in the tumor. The cut-off value was the most significant one for prognostic prediction by log-rank plot analysis.
CKS2 mRNA expression in human normal tissues. Quantitative real-time RT-PcR was performed using the Human Total RNA Master Panel (clontech, Palo Alto, cA, USA) to characterize CKS2 mRNA expression (Fig. 1D) . CKS2 expression in the testis was extremely high. In the digestive organs, the stomach, colon and small intestines, the expression was lower.
The clinicopathological significance of CKS2 mRNA expression in gastric cancer. The clinical samples were divided into two expression groups as mentioned previously. The expression of CKS2 mRNA in human gastric cancer and the correlation with clinicopathological factors are shown in Table I . Five of these factors, i.e., tumor size, the incidence of serosal invasion, the incidence of lymph node metastasis, the incidence of liver metastasis, and the incidence of advanced stage cancer (according to the criteria of the Japanese classification of Gastric Carcinoma) were significantly different in the high expression group when compared to the low expression group. On the contrary, clinicopathological factors, such as age, gender, histological grade, lymphatic invasion, venous invasion, peritoneal dissemination and distant metastasis were not significantly different between the high and low expression groups.
Relationship between CKS2 mRNA expression and prognosis.
The patients in the CKS2 high expression group had a significantly poorer prognosis than those in the CKS2 low expression group (Fig. 2A, p<0.01) . The overall five-year survival rate was significantly higher in the CKS2 low expression group (59.9%) than in the CKS2 high expression group (23.9%) (p<0.01). did not receive it (p=0.01). However, when patients were analyzed for CKS2 mRNA expression and the response to post-operative chemotherapy, no significant correlation was observed (p=0.43). Thus, the CKS2 mRNA expression did not affect the outcome of post-operative chemotherapy, but it was related to prognosis. 
5-year survival Multivariate analysis -------------------------------------------------------------------------------------------------------variables
No Immunohistochemistry of CKS2 expression. The expression of the cKS2 protein was evaluated by immunohistochemistry analysis of resected gastric cancer samples. Staining of cKS2 was markedly stronger in the human gastric cancer tissues than in the corresponding normal tissues. The expression of cKS2 was localized to the cell nucleus (Fig. 2B) . In 13 cases with above average levels of CKS2 mRNA expression, cKS2 staining in the cancer cells was strong in 9 cases, and moderate or weak in 4 cases. In contrast, in 13 cases with below average expression levels of CKS2 mRNA, cKS2 staining was strong in 4 cases, and moderate or weak in 9 cases. Thus, this shows that the level of expression of CKS2 mRNA was associated with the level of protein expression (p<0.05).
The effect of CKS2 gene suppression in a gastric cancer cell line. The highest CKS2 expression was found in MKN74 cells by real-time quantitative RT-PcR (Fig. 3A) . Therefore, we used the MKN74 cell line for subsequent experiments. CKS2-specific siRNA-suppressed cells were established. The suppression of CKS2 expression was confirmed with real-time quantitative RT-PcR (Fig. 3B) . We measured CKS2 mRNA expression 72 h after the CKS2 siRNA-RNAiMAx complex was formed. The mean expression value of CKS2 mRNA in CKS2-siRNA-suppressed cells, 1.08±0.06 (mean ± SD, normalized to GAPDH gene expression), was significantly lower than the value for the siRNA-negative control, 3.88±0.16 (p<0.01; Student's t test). We analyzed whether the suppression of CKS2 altered the growth rate of the MKN74 gastric cancer The mean expression value of CKS2 mRNA in cKS2-siRNA suppressed cells, 1.08±0.06 (mean ± SD, normalized to GAPDH gene expression), was significantly lower than the value, 3.88±0.16, in the siRNA-negative control (p<0.01). (C) MTT assay. In vitro proliferation rate of CKS2-suppressed cells. CKS2-suppressed cells were less proliferative than the siRNA-negative control (p<0.01). The data represent the means ± SD.
cell line. As shown in Fig. 3C , there was a significant difference in the growth rate between cKS2-siRNA suppressed cells and the siRNA negative-control (p<0.01).
In the clinicopathological studies, we found that tumor size was significantly larger in the CKS2 high expression group than in the CKS2 low expression group and the incidence of serosal invasion was significantly higher in the high expression group than in the low expression group (Table I) . To verify these findings in an in vitro assay, we examined the migratory and invasive potential of CKS2-siRNA cells using in vitro migration and Matrigel invasion assays. The migration assay showed that CKS2-siRNA cells had significantly less migratory capacity than the siRNA-negative control (p<0.01) (Fig. 3D) . The invasion assay showed that CKS2-siRNA cells were significantly less invasive than the siRNA-negative control (p<0.01) (Fig. 3E) . Thus, a high expression of cKS2 enhanced tumor migration and invasiveness.
In addition, we found that CKS2-siRNA cells were dramatically altered in their morphological appearance. Most of the transfected cells became rounded and loosely attached to the culture surface (data not shown). The cells were stained with the annexin v/propidium iodide dye 72 h after the CKS2-siRNA-RNAiMAx complex was formed. The assays showed that CKS2-siRNA cells had a higher frequency of apoptosis (25.1%) than the siRNA-negative control (12.9%) (Fig. 4A) . As shown in Fig. 4B , there was a significant difference in the percentages of apoptotic cells between CKS2-siRNA cells and the siRNA-negative control (p<0.01). We examined caspase 3 expression in CKS2-siRNA cells by flow cytometry. CKS2-siRNA cells had increased caspase 3 activity (10.8%) compared to the siRNA-negative control (2%), indicating that the suppression of cKS2 expression increased caspase 3 activity by at least five-fold (Fig. 4c) . To further confirm these results, Western blot analyses were carried out to assess the abundance of apoptotic markers at the protein levels. It was apparent that the knockdown of CKS2 expression increased Bax expression at the protein level (Fig. 4D) . The pathways from cKS2 to caspase 3 and Bax, are unidentified, but these results show that apoptosis is induced by inhibiting cKS2 expression.
Discussion
In the patients studied here, CKS2 was overexpressed in the gastric cancer tissues compared to the normal tissues of the (25, 26) . Furthermore, CKS2 was overexpressed in bladder cancers that were invasive compared to those that were superficial (27) .
This study demonstrates that CKS2 mRNA expression status is associated with tumor size, depth of tumor invasion in the gastric wall, lymph node metastasis and liver metastasis. The cases with high CKS2 mRNA expression tended toward larger tumor size, deeper wall invasion, positive lymph node metastasis, positive liver metastasis and, as a result, poorer prognosis compared to those with low expression.
The expression of cKS2 correlated with tumor size. The suppression of CKS2 expression by siRNA showed lower cellular proliferation and migration (Fig. 3) . cells treated with cKS2-siRNA altered their cell morphology (data not shown). We hypothesized that apoptosis would be induced by the inhibition of CKS2 expression. The suppression of CKS2 expression increased the annexin v-positive cell populations, caspase 3 activity and Bax expression at the protein levels (Fig. 4) . These results show that apoptosis is induced by inhibiting CKS2 expression. Our data are consistent with ones from other studies on other cancers (28) (29) (30) .
The expression of CKS2 correlated with serosal invasion. The suppression of CKS2 expression by siRNA showed lower invasiveness (Fig. 3E) . These results are consistent with ones from other studies on bladder (27) and colon cancer (31) . It is important to know the extent of invasion at the time of treatment of gastric cancer. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are being introduced to routine clinical practices. The determination of treatment strategy depends in part on the extent of wall invasion. For example, if invasion of the wall is limited to the mucosa, EMR or ESD would be applicable. However, if the invasion reaches the middle or deep layers of the submucosa, more aggressive surgery would be required. We are currently examining CKS2 expression in biopsy specimens that were obtained prior to surgery.
This study found that the expression of CKS2 correlated with lymph node metastasis. This finding is also consistent with findings from other studies on cervical cancers (1). We previously analyzed genes related to lymph node metastasis in human esophageal cancers. Using laser microdissection techniques and cDNA microarray, several genes were identified and found to be differentially expressed between the lymph node-positive and -negative primary tumors. One of these genes was CKS2 (32) . Thus, we consider that this gene could be associated with lymph node metastasis in a wide variety of cancers. Patients suitable for endoscopic treatments are selected by the pre-operative diagnosis of lymph node metastasis, such as macroscopic type, tumor size, presence of an ulcer, and histology of biopsy specimens. However, it is very difficult to diagnose some patients correctly, and they actually do have lymph node metastasis before surgical inter vention. By incorporating the quantitative analysis of CKS2 gene expression, pre-operative selection of patients without lymph node metastasis could be possible.
Univariate analysis demonstrated that the following were prognostic factors: Tumor size, depth of wall invasion, lymph node metastasis, lymph vessel and vascular vessel invasions, liver metastasis, peritoneal dissemination and CKS2 expression status. Multivariate analysis demonstrated that CKS2 expression status, lymph node metastasis, liver metastasis and peritoneal dissemination were independent prognostic factors for overall survival in the cox proportional hazard regression model. To our knowledge, this is the first study reporting a correlation between cKS2 expression and prognosis in gastric cancer. In the majority of gastric cancer reports, gene expression is secondary to TNM stage classification as a prognostic marker. As its expression is an independent prognostic factor, the expression profile of cKS2 could contribute to the creation of a new clinical classification system predicting lymph node metastasis.
In conclusion, we demonstrate that the expression of CKS2 in gastric cancer is elevated relative to levels in normal tissue, and that CKS2 mRNA overexpression is associated with tumor differentiation, lymph node metastasis, distant metastasis, peritoneal dissemination and poor prognosis. In particular, CKS2 mRNA overexpression is associated with prognosis, as shown by multivariate analyses. Therefore, cKS2 could be a useful predictive marker of lymph node metastasis, which could permit minimally invasive and curative treatments combining EMR and ESD in early gastric cancer.
